Last Updated: 19 Sep 2024
Executive Summary
Cocrystal Pharma Inc. (COCP) is a biotechnology company focused on developing antiviral treatments for serious and chronic viral diseases. Despite its early-stage development, the company has shown promising growth potential, with its latest quarterly revenue increasing by 0.269% year-over-year. However, the company faces challenges with negative earnings and profitability metrics.
Company Overview
Cocrystal Pharma is headquartered in Bothell, Washington, and has a market capitalization of $17.8 million. The company's focus on antiviral treatments aligns with the growing demand for innovative therapies in this field.
Fundamental Analysis
Earnings: COCP has consistently reported negative earnings per share (-$1.75 TTM) and EBITDA (-$21.15 million TTM).
Revenue: The company's revenue has shown modest growth, with a TTM of $510,000.
Profitability: COCP has negative profit and operating margins, indicating a lack of profitability.
Return on Assets/Equity: The company's ROA and ROE are both negative (-0.461 and -0.689, respectively), indicating that it is not generating sufficient returns on its assets or equity.
Technical Analysis
Price: The current stock price of $1.75 is within its 52-week range ($1.325 - $3.1).
Moving Averages: The 50-day moving average ($1.928) is above the 200-day moving average ($1.821), indicating a potential bullish trend.
Beta: COCP has a beta of 1.417, suggesting that its stock price is more volatile than the overall market.
Short Term Outlook
The short-term outlook for COCP is mixed. The company's recent revenue growth is encouraging, but its negative earnings and profitability metrics remain a concern. Investors should monitor the company's upcoming financial reports for signs of improvement.
Long Term Outlook
The long-term outlook for COCP depends on its ability to successfully develop and commercialize its antiviral treatments. The company has a promising pipeline of candidates, but it faces competition from other biotechnology companies. Investors should consider the potential risks and rewards before investing in COCP.
Analyst Recommendations
Analysts have issued the following ratings for COCP:
Buy: 2
Hold: 0
Sell: 0
Strong Buy: 0
Strong Sell: 0
The average analyst target price is $8, indicating a potential upside of over 350%. However, it is important to note that analyst recommendations can change over time.
